The Q4 Recovery Arrives, but the Cash Payoff Moves Further Out

Results vs. Consensus

Year-over-year comparison

Sequential comparison

Full-year outcome against the reset

Revenue assessment: Acquisitions contributed $282.3M of Q4 revenue, so the 133% headline growth exaggerates the underlying expansion. The more useful evidence is 31% organic growth and 30% growth against the BlueHalo-inclusive pro forma comparison. Demand converted into recognized sales at a scale that materially challenges our prior execution concern. The $233.6M sequential increase was substantially larger than the roughly $40M of shipments discussed as delayed last quarter; the rebound cannot be reduced to that one timing item.

Margin assessment: Product mix and throughput did the work. Adjusted product gross margin reached 44%, while adjusted service margin fell to 2%; consolidated adjusted gross margin recovered to 34% from 27%. Adjusted SG&A fell to 11% of quarterly sales and R&D to 5%, allowing the strong product contribution to reach EBITDA. FY27’s higher expense ratios mean that the 21.8% Q4 EBITDA margin is a demonstration of operating potential, not a sustainable annual run rate.

EPS assessment: Adjusted EPS grew 14.3% even as EBITDA more than doubled, reflecting the substantially larger post-acquisition share base and a different expense mix. GAAP net income also benefited from $14.8M of equity-method income and $7.5M of other income, including net interest income. The adjustment bridge removes $0.36 per share of investment activity while adding $0.80 of purchase-accounting charges and $0.15 of acquisition expenses: $1.25 + $0.80 + $0.15 − $0.36 = $1.84. Operating delivery, rather than those investment gains, supports the adjusted earnings beat.

Segment Performance

Pro forma comparisons include BlueHalo in the prior year; operating-group growth rates below are company-disclosed.

AxS: the dependable engine earns back that description

Precision Strike & Defensive Systems produced approximately $333M of revenue, up 80% pro forma, led by Switchblade, Red Dragon and Titan. Uncrewed Aircraft Systems grew 17% to approximately $121M, while other AxS activities contributed approximately $38M. This is a stronger recovery than merely reversing Q3’s decline: the portfolio combined higher unit delivery with materially better product profitability.

The distinction within BlueHalo matters. Titan and Freedom Eagle-1 belong to AxS, so the acquired portfolio is already helping the profitable engine. Titan sales more than doubled pro forma for FY26, and management described it as one of the combined company’s most profitable product lines. Treating every BlueHalo business as a drag would miss an important part of Q4’s success.

Assessment: AxS’s dependable-engine pillar moves back on track. The 28.2% segment EBITDA margin provides evidence of manufacturing leverage and underpins our willingness to retain a premium multiple. Sustaining that margin through a lower-volume first half will be harder, so our FY27 estimates allow for substantial quarterly variability.

SCDE: breakeven is progress, but SCAR still supported the quarter

SCDE returned to a small positive adjusted EBITDA contribution, after the prior quarter’s loss, but still generated less than 1% of segment revenue as EBITDA. Space & Directed Energy grew 23% pro forma to approximately $74M, supported by LOCUST, while Cyber & Mission Solutions declined 26% to approximately $76M.

SCAR contributed $31M in Q4 and $121M in FY26 despite the termination. FY27 excludes that revenue entirely. Consequently, the coming year begins with a replacement task: LOCUST, optical communications and other programs must first offset lost SCAR sales before producing consolidated growth. Cyber’s slow-growth outlook offers limited help. The $240M laser-communications contract won last fall and the subsequent $43M PANTHER award are useful evidence of replacement opportunities, but they are multi-period contracts rather than immediate earnings substitutes.

Assessment: The high-margin SCDE platform remains at risk. Returning to near breakeven satisfies part of our prior loss-narrowing condition, but $1.4M of quarterly EBITDA does not establish the acquisition’s intended profit contribution. Our base case relies primarily on AxS and gives SCDE time to recover rather than assuming an immediate step-up.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Management was more assured about delivery than last quarter, with a completed revenue and cash recovery to support that confidence. It remained cautious about the timing of government funding and more explicit about the near-term cost of scaling the business. The improved operating tone was tempered by the need to explain a restatement and material weakness.

1. Revenue conversion changes the prior investment case

Our last recap identified a record Q4 without another cut as a condition for returning to Hold. Revenue of $641.6M exceeded the roughly $564.8M implied by the revised full-year revenue midpoint. Adjusted EBITDA exceeded the approximately $128.9M implied by the reset, although the resulting annual total still missed the original plan. The distinction matters: the company delivered against reduced expectations, and those reduced expectations were the actionable test entering this print.

“Full year adjusted EBITDA of $286 million came in above the high end of our most recent guidance range.”
— Wahid Nawabi, Chairman, President & CEO

Assessment: Maintaining Underperform solely because earlier ramps slipped would ignore disconfirming evidence. Q4 establishes that funded demand can produce high-margin output; the rating now depends more on the price paid for that capability and the cash required to expand it.

2. Service-contract losses limit the margin recovery

Adjusted service gross margin fell from 17% to 2%, even as product margins improved sharply. Management identified costs incurred against delayed Cyber & Mission Solutions funding and a forward-loss charge on a legacy BlueHalo contract after aligning indirect rates. Calling these items one-time does not eliminate the underlying risk: cost-plus and development work can absorb overhead differently from mature product shipments, particularly when funding dates shift.

“And then there was a indirect rate realignment that took place, which has resulted in a forward loss and onetime EAC adjustment in our Precision Strike and Defensive Systems business. Those are onetime only events.”
— Sean T. Woodward, EVP & CFO

Assessment: We expect some service-margin recovery as those specific costs fade, but cannot underwrite the size of the rebound because the charges were not quantified. FY27’s EBITDA outlook already requires better gross margins to absorb increased R&D and SG&A, making this an operating assumption with meaningful downside if recovery is delayed.

3. The impairment correction adds a reporting-control risk

An additional approximately $89M charge increased the prior SCAR-related goodwill impairment to $240.7M. Management attributed the correction to omitted goodwill associated with acquired tax attributes in the Q3 impairment calculation. It said the underlying cash-flow forecast had not changed. That is a different signal from another deterioration in expected customer demand, but a material weakness in preparing and reviewing the impairment analysis remains a substantive problem.

“The impairment did not result from changes in the cash flow projections of the space reporting unit.”
— Sean T. Woodward, EVP & CFO

Sean Woodward’s first earnings call as CFO therefore combined an operating recovery with a controls repair. Management identified the error, implemented additional review procedures and said remediation requires testing over further quarters. The roughly $291M of goodwill remaining in the Space reporting unit still depends on a successful commercial transition.

Assessment: Guidance credibility improves, while financial-reporting credibility remains under pressure. We retain the execution-risk pillar and broaden it explicitly to include controls; we do not interpret the accounting correction as a second SCAR cancellation or a fresh reduction in forecast cash flows.

4. Counter-UAS makes the strongest commercialization case

AV’s counter-UAS business was roughly a couple of hundred million dollars in FY26, with Titan providing the current revenue base. LOCUST adds directed energy, while Freedom Eagle-1 adds a lower-cost kinetic interceptor. Combining those layers expands the range of drone threats AV can address and creates opportunities for common software and customer relationships across products.

“We have a very crisp and clean strategy on a layered defense approach to counter UAS or defending against drones. We do not believe just in 1 solution set or 1 technology. We have a multilayered solution set and approach to it.”
— Wahid Nawabi, CEO

LOCUST’s maritime demonstration, domestic airspace clearance and planned full-rate production improve its route to adoption. The Army’s EHEL competition is a consequential next step: management described an approximately $5B program with an award expected in the next few months. That figure is the program opportunity, not an AV award. The announced $30M Albuquerque expansion increases the cost of being ready before that decision.

Assessment: Counter-UAS is the most persuasive reason to preserve value for SCDE’s commercialization potential. Our bull case requires funded production decisions and repeat orders; the base case does not assume AV captures the EHEL program’s full value.

5. New products expand the opportunity before capacity earns a return

Switchblade 400’s LASSO selection and Mayhem 10’s common-launch-tube design extend the franchise beyond existing dismounted applications. Red Dragon received a $17M production contract during Q4. P550’s $117M Army award followed quarter-end, while VAPOR CLE’s roughly $15M award adds another reconnaissance program. These wins diversify future production demand, but development milestones, appropriations and customer acceptance determine the earnings timetable.

“Progress continues on our Salt Lake City manufacturing facility, which has the potential to produce more than $2 billion worth of switchblades or other AV products per year. We are on track to begin production in the spring of calendar year 27.”
— Wahid Nawabi, CEO

The spring timetable for Salt Lake City places the new facility near FY27’s end; management also used earlier-calendar-year language elsewhere on the call. We assume no large full-year output contribution from that site in FY27. Its potential capacity of more than $2B of annual product value is installed capability, not booked revenue. Freedom Eagle-1 remains in development with flight testing expected in approximately 12 months, adding a further lag between today’s investment and scalable sales.

Assessment: The product pipeline supports multi-year growth and a premium valuation, but an early capacity ramp should be upside to the base case. Spending ahead of program timing becomes costly if customer decisions slip, even when the equipment can serve multiple products.

6. Q4 cash recovery does not end the funding requirement

Management reported $73M of Q4 free cash flow and described work with the government to streamline Switchblade acceptance. Faster acceptance can shorten the interval between manufacturing, recognition, billing and payment. The year still used $78.4M of operating cash, including $129M absorbed by receivables, $159M by unbilled balances and $112M by inventory, before offsetting items.

“During quarter 4 of fiscal year 26, we worked closely with the US government to streamline the Switchblade acceptance process. We believe this procedural improvement will shorten our cash conversion cycle and improve working capital efficiency going forward.”
— Sean T. Woodward, EVP & CFO

Assessment: Acceptance improvements address a specific working-capital problem raised in the prior recap, but new capacity spending now dominates the cash outlook. At the FY27 revenue midpoint, the 12–14% capex plan implies $261–305M, including software and cloud implementation. Our base case assumes $65M of cash use and therefore higher net debt at the valuation horizon, despite another year of positive adjusted earnings.

7. International expansion consumes operating leverage

Management is adding sales and business-development resources internationally while raising R&D to 7–9% of revenue. Adjusted SG&A rises to 14–16%, compared with 13% for FY26. Greater overseas adoption could reduce reliance on a single U.S. budget cycle, but qualification, export approvals and local support create costs before orders scale.

“1 of the key areas that we are investing in fiscal 27 in terms of SG&A is international expansion to have better presence in these markets based on requests and signals that we are getting from specific countries around the world.”
— Wahid Nawabi, CEO

Assessment: International reach is a plausible long-term return on spending, not an immediate margin offset. Holding annual EBITDA margin around 14.5% while these expense ratios rise requires a better gross-profit mix; the FY27 outlook is not conservative on every cost assumption just because it is cautious about funding.

8. Backlog quality matters more than headline award totals

Quarterly authorized bookings of $572M were below $641.6M of revenue, leaving book-to-bill at 0.9x. Full-year bookings of $2.7B and 1.4x book-to-bill support continued demand, while funded backlog increased to about $1.2B. The FY27 visibility figure of 69% includes anticipated bookings and unfunded conversion alongside funded backlog. A portion of the sales plan therefore still depends on awards and appropriations arriving on schedule.

“Our book to bill ratio for the fourth quarter was 0.9x, reflecting the exceptional quarter 4 revenue performance partially offset by some timing delays anticipated large program awards.”
— Sean T. Woodward, EVP & CFO

Assessment: A sub-one quarterly ratio following a large shipment quarter is not evidence that demand has collapsed. It does mean the recovery now needs replenishment. Funded conversion, rather than larger program ceilings, is the most useful test of whether the stronger output pace can persist.

Guidance & Outlook

The revenue guide is essentially in line with the roughly $2.17B consensus, but the $3.18 EPS midpoint is 19.3% below the $3.94 expectation. Replacing $121M of FY26 SCAR revenue means the remaining businesses need approximately $319M of additional sales to reach the $2.175B midpoint, equivalent to 17.2% growth against FY26 excluding SCAR. That calculation includes acquisition contribution; it is not an organic-growth forecast.

Depreciation and cloud amortization rise from approximately $47.6M to $84M, absorbing more than the $28.9M increase in EBITDA at the midpoint. Higher stock compensation also weighs below adjusted EBITDA. The company can grow sales and maintain its EBITDA margin while adjusted EPS falls because the capital base is being built ahead of revenue.

The implied quarterly ramp

The cadence allocates 45% of annual revenue to the first half and 45% of that half to Q1; EBITDA allocates one-third to the first half and one-third of that amount to Q1. EPS allocates 25% to the first half and 25% of that to Q1. Q1 revenue would fall approximately 3% from the prior year’s $454.7M, with EBITDA margin around 8%. The second half then needs roughly 17.6% EBITDA margin on 55% of annual sales.

Guidance assessment: Management assumes a continuing resolution and delayed access to the next U.S. defense budget, potentially until March. This makes the revenue timing cautious, but repeats the dependence on a profitable back half that worried us last quarter. Q4 has now shown that such a ramp is achievable; the new spending program makes it expensive if the ramp misses. We use the midpoint and treat earlier funding as upside, rather than assuming another automatic beat.

Analyst Q&A Highlights

What actually changed in the goodwill calculation?

The question challenged the remaining goodwill after the restatement. The response isolated an accounting error and described the remaining remediation work, separating reporting reliability from the operating forecast.

Q: “And then just to clean up, can you just touch on the goodwill impairment? You disclosed the additional you restated it last week. How do we think about the $1.2 billion left on the balance sheet? And if you could help bridge us as we look forward to 2027 as it relates to scar.”
— Sheila Kahyaoglu, Jefferies

A: “The additional impairment was filed due to an error in the Q3 calculation, in which an estimated allocation of goodwill associated with the acquired tax asset attributes were not included in the measurement of goodwill impairment for the space reporting unit. As disclosed in our 8 k, we filed with the SEC. The error was detected by management. A third party accounting firm was engaged to prepare the Q3 goodwill impairment analysis The error in the third quarter by the third party was identified by management, detected, and corrected in the fourth quarter. Additional internal controls have been implemented and were executed in Q4 to prevent this potential for future errors. These controls will need to be tested for additional quarters in order to remediate the SOX control error. Related to the overall goodwill in the space and cyber directed energy business, it is $1.2 billion, and the remaining of that is $291 million associated with the space business unit specifically.”
— Sean T. Woodward, EVP & CFO

Assessment: The explanation supports treating the additional charge as a calculation correction, not another demand downgrade. It does not establish that controls are already effective: management said additional quarters of testing are required. This keeps the reporting-risk discount relevant even after better earnings delivery.

How much cash does the capacity build consume?

A follow-up to the funding discussion asked whether increased capital spending leaves any free cash flow. Management gave a clear direction but no quantified cash-flow range.

Q: “And then maybe just a follow-up, the investments. That you mentioned, it is a pretty significant step up in CapEx and I think we you talked about some of the drivers of that. Where do you expect free cash flow to come in for the year?”
— Seth Seifman, JPMorgan

A: “From a free cash flow perspective, we are not expecting fiscal year 27 to be positive on free cash flow. Given the amount of CapEx that we are planning on spending during the year.”
— Sean T. Woodward, EVP & CFO

Assessment: The negative answer limits the significance of Q4’s cash rebound for valuation. Our $65M cash-use assumption is an analyst estimate; a larger inventory or acceptance delay would increase debt at the same time that it pressures earnings. The bear case therefore combines lower EBITDA with greater net debt.

How much of FY27 growth is organic?

The question sought a separation of acquisition contribution from underlying growth. Management repeated the total-company growth forecast and disclosed only the recent acquisition’s FY26 contribution.

Q: “I mean, just can you call out what organic growth is implied in the FY 27 outlook?”
— Andre Madrid, BTIG

A: “We do not really provide breakdowns below that, but overall, we are expecting 10% year over year growth. ES Aero contributed from the time of acquisition to the end of fiscal year 26 around $20 million to fiscal year 26 totals.”
— Sean T. Woodward, EVP & CFO

Assessment: The answer leaves the organic-versus-acquired bridge open. Annualizing ESAero helps replace SCAR but does not establish faster demand in the existing portfolio. We forecast the consolidated midpoint without describing the implied ex-SCAR growth as organic.

Why should the supply chain support a faster ramp?

The exchange tested whether simultaneous product expansions might reproduce the shipment constraints raised last quarter. Management described both supplier diversification and investment in supplier throughput.

Q: “Just given the various platforms that you are in the process of ramping aggressively, do you feel like the supply chain is prepared to support that level of growth?”
— Michael Leshock, KeyBanc Capital Markets

A: “We are not only just expanding our manufacturing footprint ourselves, part of the CapEx investment and initiative that we have within the company this year to significantly ramp up several platforms in the multiples in terms of growth targets at capacity wise is to work with our suppliers to expand the number of suppliers and also help our suppliers increase their throughput.”
— Wahid Nawabi, CEO

Assessment: This identifies a concrete response to bottlenecks rather than relying solely on AV’s own factory space. It still does not quantify supplier readiness or delivery coverage. Q4 supports greater confidence in existing production; it cannot establish that several new platforms will ramp simultaneously without working-capital pressure.

How does higher spending coexist with flat EBITDA margin?

The question asked for the bridge from FY26 margins to FY27 despite increased R&D and selling costs. Management explicitly relied on improved product and service gross margins.

Q: “Maybe just on margins, can you help us bridge fiscal 27 versus 2026? I know there is fair amounts of puts and takes and appreciate you calling out the changes in SG&A and IRAD. But any other color you can give on that would be helpful.”
— Jonathan Siegmann, Stifel

A: “But we are able to increase the overall R&D investment between 7% to 9% and SG&A between 14% to 16%. That increased investment is gonna come from improved adjusted gross margins from our product sales and overall services mix that we are going to have in fiscal year 2027.”
— Sean T. Woodward, EVP & CFO

Assessment: The forecast spends the gross-margin recovery before it reaches EBITDA margin. This is coherent if service losses fade and product mix holds, but leaves little protection if either disappoints. We therefore retain a 14.5% annual EBITDA margin rather than annualizing Q4’s 21.8%.

Why does the first quarter imply a revenue decline?

The question challenged the weak opening quarter embedded in a full-year growth forecast. Management attributed it to the missing SCAR business and the timing of awards expected later in the summer.

Q: “I know quarter to quarter, super lumpy, but if I am doing the math right, it implies first quarter will be down year over year. Anything specific behind that?”
— Kevin Parsons, UBS

A: “We have the stop work on SCAR is leaving around a $30 million hole as well as some of the order timings coming through later this summer that we expect to ramp up the back half of fiscal year 2027.”
— Sean T. Woodward, EVP & CFO

Assessment: The implied decline is already part of the outlook, so a soft Q1 alone would not refute the recovery. The consequential test is whether the expected summer awards support Q2 and the second half. Further delays without an offsetting funded backlog would weaken the Hold case.

What They’re NOT Saying

1. A segment earnings bridge for SCDE: The quarter establishes near breakeven, but no FY27 segment-margin target explains how LOCUST and communications replace SCAR profitability. Without that bridge, our base case does not depend on a sudden SCDE margin expansion.
2. The dollar size of service-contract charges: Management called the delayed-funding costs and contract revision one-time but did not quantify them when asked. Their absence prevents a confident estimate of normalized service gross profit.
3. A quantified FY27 free-cash-flow range: Negative cash flow is explicit; its magnitude is not. Working-capital requirements could turn an earnings recovery into a substantially larger financing need.
4. A reconciliation of ESAero and organic growth: The consolidated guide embeds acquisition annualization and the loss of SCAR without separating their full-year effects. The 10% revenue growth target cannot be read as 10% organic growth.
5. A dated controls-remediation endpoint: New procedures require testing over additional quarters. Better Q4 execution does not resolve whether the expanded company can consistently prepare reliable complex valuations.

Market Reaction

• Pre-print setup: AVAV closed at $139.00 on June 29, down 42.5% year to date, 32.9% over the trailing 30 days and 50.0% over the trailing 12 months. The pre-print 52-week closing range was $136.68–$409.83.
• Reaction session, June 30: Shares opened at $176.50, traded between $157.79 and $178.50, and closed at $165.07, up 18.8%. Volume was 8.0M shares against a 1.4M 30-day average, or 5.7x normal activity.
• Market comparison: The S&P 500 gained 0.8% in the reaction session and had entered the print up 8.7% year to date.

The most persuasive interpretation is relief that the operating recovery arrived after a severe de-rating. Contemporaneous coverage emphasized the quarterly beat and AxS strength; the FY27 EPS shortfall did not prevent a large advance. That is consistent with expectations embedded in the stock having fallen further than the published earnings consensus.

The close below the opening price also matters. Buyers recognized a better business outcome but did not sustain the initial gap. We do not treat that intraday pattern as proof of a particular positioning unwind; it fits a report that repairs the execution case while leaving investors to fund another substantial investment year.

Street Perspective

Debate: does a delivered Q4 restore the growth case?

Bull view: The revenue and profit beat confirms that prior delays were recoverable. A 31% organic growth quarter and strong product margins demonstrate that AV can turn its defense exposure into earnings.

Bear view: The year still missed its original EBITDA plan, SCDE contributed little profit, and FY27 opens with another weak quarter and a heavy second-half requirement.

Our take: The bulls have the stronger argument about Q4 execution; the bears retain the stronger challenge to repeatability. That combination invalidates a reflexive Underperform while falling short of the track record needed for Outperform.

Debate: prudent capacity spending or capital ahead of orders?

Bull view: Winning programs and rapid counter-UAS adoption justify building capacity before customers need it. Existing franchises and supplier relationships improve AV’s ability to capture urgent procurement.

Bear view: Capex approaching the size of annual EBITDA, negative free cash flow and uncertain appropriations put shareholders at risk if the anticipated contracts arrive late.

Our take: The investment has a credible industrial purpose, but the cash commitment is immediate and the incremental earnings are delayed. We charge the base valuation for cash use and reserve the larger earnings outcome for a funded-award bull case.

Debate: has the de-rating removed the valuation problem?

Bull view: A materially lower price and recovered operating performance make a multi-year drone and counter-UAS franchise more accessible.

Bear view: At roughly 27x FY27 adjusted EBITDA and 52x adjusted EPS, the stock still requires sustained growth while earnings per share are flat to down and cash flow is negative.

Our take: The price is now close enough to a supportable base value to justify Hold. It is not low enough to absorb the downside from renewed shipment delays, a weak SCDE recovery or poor returns on the capacity build.

Our Estimates & Valuation

Earnings bridge: Our $2.175B revenue and $315M EBITDA estimates adopt the guidance midpoints rather than extending the Q4 run rate. The roughly $29M EBITDA increase is more than absorbed by approximately $36M of incremental depreciation and cloud amortization before interest, tax, stock compensation and share-count effects. The resulting $3.18 adjusted EPS assumption is consistent with management’s midpoint; GAAP EPS guidance remains only $0.16–$0.48 because purchase accounting continues to dominate the reconciliation.

Valuation method: We value FY27 adjusted EBITDA at the end of a consistent 12-month horizon. At $165.07, 51M assumed valuation shares and approximately $35M of current net debt imply $8.45B of enterprise value, or 26.8x FY27 EBITDA. We use the roughly $748M convertible principal less $713M of cash and investments for net debt and assume no dividend. The 51M share base allows modest dilution above the 50.61M shares outstanding at year-end.

Our 28.5x base multiple is an analyst judgment that assigns a growth premium to proven AxS franchises and emerging counter-UAS products. Q4’s 31% organic growth and 28.2% AxS EBITDA margin support that premium; SCDE’s weak profitability, the control failure and negative cash flow limit it. EBITDA is useful across acquisition amortization differences, but it understates the cash cost of growth; we reflect that cost through $100M of forward net debt in the base case.

The base calculation is (28.5 × $315M − $100M) ÷ 51M = $174.07. We assume approximately $218M of operating cash flow, or 69% of EBITDA, as slower growth and faster customer acceptance reduce working-capital absorption. After approximately $283M of capex, $65M of cash use raises net debt from roughly $35M to $100M. This cash-conversion assumption would be too optimistic if receivables and inventory keep absorbing cash at FY26’s pace. The bear case combines delayed awards, 13.5% EBITDA margin and greater working-capital absorption; the bull case assumes faster funded adoption and 16.2% EBITDA margin as product mix improves. These are analyst scenarios, not additional company guidance.

Return judgment: The base case’s approximately 5–6% price return, with no dividend assumed, is broadly comparable with our 7% nominal 12-month S&P 500 return assumption. The wide range between the bear and bull cases is why modest apparent upside does not justify Outperform. Q4 improves the odds of executing the base case; funded awards and cash conversion must now support it.

Thesis Scorecard Post-Earnings

Overall: The case improves because the engine that was supposed to fund the transformation delivered. The prior recap’s conditions for reconsidering Underperform included a clean Q4, narrowing SCDE losses or a valuation reset. Operating delivery and the lower valuation now support that reconsideration, with SCDE providing only partial confirmation. The accounting weakness and cash investment prevent a broader declaration that the transformation is complete.

What would change the view: Repeated delivery against the FY27 cadence, funded counter-UAS production awards and a quantified path through the negative cash-flow year could justify Outperform if the price still offers sufficient return. Another guidance reduction caused by avoidable shipment delays, continued service-contract losses or an increase in cash use toward our bear assumptions would reopen the Underperform case. A weak Q1 already contemplated by the outlook would not, by itself, meet that test.

Action: Upgrade to Hold from Underperform. AV has earned credit for the recovery it delivered; at $165.07, the stock offers roughly the return of our broad-market base assumption with much wider operating outcomes. We would wait for stronger evidence of funded growth and cash returns before paying for the bull case.